Results 11 to 20 of about 229,203 (309)
Frontiers in Medicine, 2022 BackgroundHepatic fibrosis is a health challenge due to the absence of satisfactory therapy, especially at the cirrhosis stage. Dahuang Zhechong pill (DHZCP)-based therapy is reportedly a successful treatment for hepatic fibrosis and is even beneficial ...
Zhen Ye +11 more
doaj +1 more source
Primary hepatic lymphoma in liver cirrhosis: A rare case report
Radiology Case Reports, 2021 Primary hepatic lymphoma is rare. Clinical and radiological presentations are not specific. The diagnosis is often late. Chronic hepatitis or cirrhosis, especially post-viral C usually precedes primary liver lymphoma.
Kaoutar Imrani +4 more
doaj +1 more source
Russian Open Medical Journal, 2019 Study purpose is to demonstrate the dynamics of mortality due to hepatic cirrhosis according to forensic medical autopsy data over the period from 2007 to 2016.
Yuri I. Pigolkin +3 more
doaj +1 more source
Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis [PDF]
, 2013 Background and Aims: In patients with advanced liver cirrhosis due to chronic hepatitis C virus (HCV) infection antiviral therapy with peginterferon and ribavirin is feasible in selected cases only due to potentially life-threatening side effects ...
Dultz, Georg +11 more
core +2 more sources
BMC Gastroenterology, 2008 Background Hepatic encephalopathy has a negative impact on health-related quality of life (QoL) in liver cirrhosis. There are scarce and conflicting data on whether type or etiology of liver cirrhosis could be related to hepatic encephalopathy in ...
Björnsson Einar +2 more
doaj +1 more source
Hepatic Regeneration in Cirrhosis [PDF]
Journal of Clinical and Experimental Hepatology, 2022 End-stage liver disease is characterized by massive hepatocyte death resulting in clinical decompensation and organ failures. Clinical consequences in cirrhosis are the results of the loss of functional hepatocytes and excessive scarring. The only curative therapy in advanced cirrhosis is orthotropic liver transplantation, but the clinical demand ...
Ankur Jindal +2 more
openaire +2 more sources
Idiopathic noncirrhotic portal hypertension: current perspectives [PDF]
, 2016 The term idiopathic noncirrhotic portal hypertension (INCPH) has been recently proposed to replace terms, such as hepatoportal sclerosis, idiopathic portal hypertension, incomplete septal cirrhosis, and nodular regenerative hyperplasia, used to describe ...
D'AMATI, Giulia +5 more
core +1 more source
Prothrombine and activated partial thromboplastin time are prolonged in hepatic cirrhosis
Universa Medicina, 2016 Background Chronic hepatitis and hepatic cirrhosis are chronic liver diseases that cause disorders of liver function, such as the formation of platelets and coagulation factors (prothrombin time/PT and activated partial thromboplastin time/APTT ...
Edward Kurnia Setiawan Limijadi +2 more
doaj +1 more source
Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study [PDF]
, 2017 Background: Since direct-acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV) infection, a small series of patients with new-onset neuropsychiatric alterations have been referred to us.
Amodio, Piero +11 more
core +1 more source
Hepatic arterial vasodilation is independent of portal hypertension in early stages of cirrhosis. [PDF]
PLoS ONE, 2015 The compensatory increase in hepatic arterial flow with a decrease in portal venous flow is known as the hepatic arterial buffer response. In cirrhosis with elevated portal pressure, the vascular resistance of the hepatic artery is decreased.
Miriam Moeller +4 more
doaj +1 more source